FDA Approves First Drug for Myelofibrosis With Thrombocytopenia

Pacritinib is indicated specifically for patients with myelofibrosis and very low platelet counts, which develop in about one third of patients.
FDA Approvals

source https://www.medscape.com/viewarticle/969389?src=rss

Comments

Popular posts from this blog

New AAFP practice guideline sets blood pressure targets for adults with hypertension